Back to Authors

Srisuwananukorn, Andrew

0000-0002-8736-8726

Mayo Clinic

The Ohio State University, Columbus, Ohio, United States.

Citations 1

Systematic Review Supporting the American Society of Hematology Practice Guidelines on the Management of Myelofibrosis

Blood Advances | November 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026021619 | PMID 43063918

Myelofibrosis (MF) is a Philadelphia-negative clonal disorder of hematopoietic stem cells associated with substantial clinical practice variation. The American Society of Hematology (ASH) convened a guideline panel that prioritized ten clinical questions to inform evidence-based recommendations. We performed a comprehensive systematic review of MEDLINE, EMBASE, Cochrane databases, and Scopus through January 2025 to identify studies that addressed the ten clinical questions. Meta-analyses were performed where feasible. Two reviewers independently selected and appraised studies. Certainty of evidence was assessed using GRADE. Of 3,007 records screened, 43 unique studies met inclusion criteria for the ten questions. Extended molecular testing identified high-risk mutations (ASXL1, EZH2, SRSF2, IDH1/2) that were significantly associated with decreased overall survival (hazard ratios ranging 1.5-4.5). JAK inhibitors improved spleen and symptom responses in symptomatic lower-risk MF and in patients with anemia, with momelotinib improving transfusion independence. However, survival effects were not clearly demonstrated and hematologic toxicity remained common. Evidence for treating asymptomatic high-risk patients with JAK inhibitors was particularly limited. Early allogeneic hematopoietic cell transplantation was associated with higher early mortality but improved long-term survival compared with delayed transplantation. Pretransplant JAK inhibitor exposure did not significantly affect mortality, GVHD, or graft failure. Evidence for interferon, aspirin, and iron chelation was limited and largely indirect. The certainty of evidence was very low or low across nearly all outcomes.